We enrolled women with HER@-positive early breast cancer and randomly assigned them to receive oral lapatinib ( @ mg ) , intravenous trastuzumab ( @ mg/kg loading dose followed by @ mg/kg ) , or lapatinib ( @ mg ) plus trastuzumab ( same dose as for single agent ) in combination for @ weeks , followed by an additional @ weeks of the assigned anti-HER@ therapy in combination with weekly paclitaxel ( @ mg/m ( @ ) ) .